Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 2/20 | 0.47 |
| ▸ | WDR77 | Q9BQA1 | 2/20 | 0.47 |
| ▸ | GRM5 | P41594 | 4/20 | 0.47 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.44 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.44 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.43 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.43 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 8/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | HTR2B | P41595 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1817669 | 0.88 | GRM5 (0.61) | PRMT5WDR77GRM5SRD5A1KCNH2 | |
| SCHEMBL24168658 | 0.84 | GRM5 (0.58) | PRMT5WDR77GRM5SRD5A1HRH3 | |
| SCHEMBL30334931 | 0.84 | GRM5 (0.58) | PRMT5WDR77GRM5SRD5A1HRH3 | |
| SCHEMBL1029578 | 0.84 | HSD17B3 (0.49) | PRMT5WDR77GRM5PARP10PARP11 | |
| SCHEMBL27822202 | 0.84 | PRMT5 (0.47) | PRMT5WDR77GRM5PARP10PARP11 | |
| SCHEMBL30162812 | 0.84 | PRMT5 (0.53) | PRMT5WDR77GRM5PARP10PARP11 | |
| SCHEMBL24934195 | 0.84 | PRMT5 (0.53) | PRMT5WDR77GRM5PARP10PARP11 | |
| SCHEMBL17511486 | 0.83 | GRM5 (0.57) | PRMT5WDR77GRM5SRD5A1HRH3 | |
| SCHEMBL8001449 | 0.83 | GRM5 (0.48) | GRM5PARP10PARP11SRD5A1CYP2D6 | |
| SCHEMBL3654900 | 0.82 | PRMT5 (0.51) | PRMT5WDR77GRM5PARP10PARP11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113264920-B | CDK6 inhibitor of pyrimidine benzo six-membered ring parent nucleus and preparation method and application thereof | 中国药科大学 | 2022-09-02 | — | — | CN | disclosed |
| EP-3453707-B1 | BENZAZEPINE DERIVATIVE, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF | SHANGHAI DE NOVO PHARMATECH CO LTD (CN) | 2022-02-16 | — | — | EP | disclosed |
| CN-113264920-A | CDK6 inhibitor of pyrimidine benzo six-membered ring parent nucleus and preparation method and application thereof | 中国药科大学 | 2021-08-17 | — | — | CN | disclosed |
| US-10669252-B2 | Benzazepine derivative, preparation method, pharmaceutical composition and use thereof | Shanghai De Novo Pharmatech Co., Ltd. (CN) | 2020-06-02 | — | — | US | disclosed |
| US-20190152941-A1 | BENZAZEPINE DERIVATIVE, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF | Shanghai De Novo Pharmatech Co., Ltd. (CN) | 2019-05-23 | — | — | US | disclosed |
| EP-3453707-A1 | BENZAZEPINE DERIVATIVE, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF | Shanghai de Novo Pharmatech Co., Ltd. (CN) | 2019-03-13 | — | — | EP | disclosed |
| US-7144894-B2 | Sulfonamide bicyclic compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-12-05 | — | — | US | disclosed |
| WO-2006034480-A2 | SULFONAMIDE BICYCLIC COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-03-30 | — | — | WO | disclosed |
| WO-2006034480-A2 | SULFONAMIDE BICYCLIC COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-03-30 | — | — | WO | disclosed |
| US-20060063799-A1 | Sulfonamide bicyclic compounds | BRISTOL-MYERS SQUIBB COMPANY | 2006-03-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060063799-A1 | Sulfonamide bicyclic compounds | APP, BACE1, IAPP | PRMT5 3308/4885WDR77 4429/4885GRM5 4093/4885 |
| US-10669252-B2 | Benzazepine derivative, preparation method, pharmaceutical composition and use thereof | TLR8, TLR1, TLR5 | PRMT5 2649/4885WDR77 2528/4885GRM5 225/4885 |
| US-20190152941-A1 | BENZAZEPINE DERIVATIVE, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF | TLR8, TLR1, TLR5 | PRMT5 2649/4885WDR77 2528/4885GRM5 225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.